
Firefly Biorevenue
South San Francisco, CaliforniaFounded 2022
Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders, developing a novel platform to treat cancer.
Firefly Bio revenue
Firefly Bio has not published its revenue. Growjo puts it at about $7.4M a year (September 2025).
$0
$2M
$4M
$6M
$0
–
$7.4M
20222023–242025
| As of | Revenue | Source |
|---|---|---|
| Sep 2025 | $7.4MEST | Growjo estimate |
Firefly Bio employees
Firefly Bio has 28 employees (September 2025, LinkedIn).
0
10
20
28
2025
Firefly Bio FAQ
Categories
Companies in
How this page is sourced
1 from public sources · 1 estimate. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 10, 2026Data disclaimerReport a correctionClaim this profileRun Firefly Bio? Join the podcast